CureVac inks lung cancer vax partnership with Boehringer; DynPort sues Lonza over vaccine manufacturing subcontract;

> CureVac has banked a $45 million upfront payment from Boehringer Ingelheim to partner its therapeutic lung cancer vaccine with the German pharma's Gilotrif. More

> DynPort Vaccine, which develops vaccines for the military, has sued Lonza Biologics, alleging the company backed out of a subcontract to manufacture a vaccine and made off with $18.9 million. Report (sub. req.)

> A law firm representing the bulk of patients who developed narcolepsy after being vaccinated with GlaxoSmithKline's ($GSK) swine flu shot Pandemrix does not expect to go to trial before March of 2016. Report

> The Japanese Global Health Fund has awarded a combined $33.5 million to companies and orgnizations including Takeda, Eisai and the PATH Malaria Vaccine Initiative to fund vaccine and drug development for neglected diseases. Release

> GlaxoSmithKline's vaccines unit has agreed to pay a civil penalty of $172,900 to resolve a Clean Air Act violation from a facility in Hamilton, MT. Report

> With Texas Gov. Rick Perry in attendance, Texas A&M University will dedicate a pandemic influenza vaccine facility Thursday. More

And Finally... Vaccination rates in elite Los Angeles schools are now worse than in Southern Sudan. More